Literature DB >> 35107186

L-fucose, a sugary regulator of antitumor immunity and immunotherapies.

Emma Adhikari1,2,3, Qian Liu1,2,3, Chase Burton1,2,3,4,5, Andrea Mockabee-Macias1,2,3, Daniel K Lester1,2,3, Eric Lau1,2,3.   

Abstract

l-fucose is a dietary sugar that is used by cells in a process called fucosylation to posttranslationally modify and regulate protein behavior and function. As fucosylation plays essential cellular functions in normal organ and immune developmental and homeostasis, it is perhaps not surprising that it has been found to be perturbed in a number of pathophysiological contexts, including cancer. Increasing studies over the years have highlighted key roles that altered fucosylation can play in cancer cell-intrinsic as well as paracrine signaling and interactions. In particular, studies have demonstrated that fucosylation impact tumor:immunological interactions and significantly enhance or attenuate antitumor immunity. Importantly, fucosylation appears to be a posttranslational modification that can be therapeutically targeted, as manipulating the molecular underpinnings of fucosylation has been shown to be sufficient to impair or block tumor progression and to modulate antitumor immunity. Moreover, the fucosylation of anticancer agents, such as therapeutic antibodies, has been shown to critically impact their efficacy. In this review, we summarize the underappreciated roles that fucosylation plays in cancer and immune cells, as well as the fucosylation of therapeutic antibodies or the manipulation of fucosylation and their implications as new therapeutic modalities for cancer.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  cancer; fucosylation; immunotherapy; l-fucose; tumor immunology

Mesh:

Substances:

Year:  2022        PMID: 35107186      PMCID: PMC9097813          DOI: 10.1002/mc.23394

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   5.139


  93 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Correction of leukocyte adhesion deficiency type II with oral fucose.

Authors:  T Marquardt; K Lühn; G Srikrishna; H H Freeze; E Harms; D Vestweber
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

3.  Isolation and partial characterization of a novel amino sugar-containing fucan sulfate from commercial Fucus vesiculosus fucoidan.

Authors:  T Nishino; C Nishioka; H Ura; T Nagumo
Journal:  Carbohydr Res       Date:  1994-03-04       Impact factor: 2.104

4.  Structure of human POFUT1, its requirement in ligand-independent oncogenic Notch signaling, and functional effects of Dowling-Degos mutations.

Authors:  Brian J McMillan; Brandon Zimmerman; Emily D Egan; Michael Lofgren; Xiang Xu; Anthony Hesser; Stephen C Blacklow
Journal:  Glycobiology       Date:  2017-08-01       Impact factor: 4.313

5.  Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease.

Authors:  S Thompson; C A Kelly; I D Griffiths; G A Turner
Journal:  Clin Chim Acta       Date:  1989-10-16       Impact factor: 3.786

6.  Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.

Authors:  Laetitia Malphettes; Yevgeniy Freyvert; Jennifer Chang; Pei-Qi Liu; Edmond Chan; Jeffrey C Miller; Zhe Zhou; Thu Nguyen; Christina Tsai; Andrew W Snowden; Trevor N Collingwood; Philip D Gregory; Gregory J Cost
Journal:  Biotechnol Bioeng       Date:  2010-08-01       Impact factor: 4.530

7.  FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.

Authors:  Salina Louie; Benjamin Haley; Brett Marshall; Amy Heidersbach; Mandy Yim; Martina Brozynski; Danming Tang; Cynthia Lam; Bronislawa Petryniak; David Shaw; Jeongsup Shim; Aaron Miller; John B Lowe; Brad Snedecor; Shahram Misaghi
Journal:  Biotechnol Bioeng       Date:  2016-10-04       Impact factor: 4.530

8.  Leukocyte adhesion deficiency (LAD) II.

Authors:  A Etzioni; L M Phillips; J C Paulson; J M Harlan
Journal:  Ciba Found Symp       Date:  1995

9.  First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

Authors:  Khanh T Do; Laura Quan Man Chow; Karen Reckamp; Rachel E Sanborn; Howard Burris; Francisco Robert; D Ross Camidge; Conor E Steuer; John H Strickler; Amy Weise; Jennifer M Specht; Martin Gutierrez; Peter Haughney; Shawna Hengel; Christina Louise Derleth; Timothy A Yap
Journal:  Oncologist       Date:  2021-09-22

10.  2-Fluoro-L-Fucose Is a Metabolically Incorporated Inhibitor of Plant Cell Wall Polysaccharide Fucosylation.

Authors:  Jose A Villalobos; Bo R Yi; Ian S Wallace
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.